CLCN2: Chloride channel protein 2
Voltage-gated and osmosensitive chloride channel.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CLCN2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Lubiprostone | Approved | Mallinckrodt | Small molecule | OpenerChloride channel protein 2 opener | 3 |
| Cobiprostone | Phase 2 | Mallinckrodt | Small molecule | ActivatorChloride channel protein 2 activator | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.| Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer | Lubiprostone | Phase 2 | Not yet recruiting | Sun Yat-sen University | Feb 12, 2026 |
| Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation | Lubiprostone | Phase 3 | Recruiting | Third Military Medical University | Dec 11, 2025 |
| Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation | Lubiprostone | — | Recruiting | BioDelivery Sciences International | Oct 25, 2018 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Leukoencephalopathy with mild cerebellar ataxia and white matter edema
- 0.81
- Familial hyperaldosteronism type II
- 0.75
- Constipation disorder
- 0.59
- Chronic pain
- 0.37
- Bowel dysfunction
- 0.35
- Intelligence
- 0.31
- Cerebral palsy
- 0.27
- Non-alcoholic fatty liver
- 0.26
- Chronic constipation
- 0.24
- Hereditary disease
- 0.20
- Epilepsy
- 0.15
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1628478, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P51788, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets